PLYMOUTH, Michigan — Esperion Therapeutics, a spin-off from Pfizer Inc., has raised an additional $5 million to develop drugs that treat cardiovascular and metabolic disease, according to a Securities and Exchange Commission filing.
The regulatory document states that Esperion has raised $27.75 million in equity and debt, but that dollar figure likely includes a $22.75 million Series A fundraise the company announced in 2008 after the spin-off.
Esperion said in the document that it’s looking to raise $38.25 million. It’s unclear what the company’s plans are for a Series B round. An Esperion spokesman didn’t comment.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company’s flagship drug, ETC-1002, is designed to treat dyslipidemia, a disorder in which too many fatty substances are present in a patient’s blood. In November, Esperion launched a Phase 1 clinical trial of the drug. The drug works by lowering a patient’s so-called “bad” cholesterol (low-density lipoproteins) and raising levels of “good” cholesterol (high-density lipoproteins).
The Series A round was co-led by New York-based Aisling Capital, California-based Alta Partners and New Jersey-based Domain Associates, and included participation by Michigan-based Arboretum Ventures. Pfizer also retained a financial stake in Esperion.
Esperion Chief Executive Dr. Roger Newton co-founded the company in 1998, took it public, then sold it in 2004 to Pfizer for $1.3 billion. He restarted Esperion after Pfizer shuttered it in 2007 as the giant pharmaceuticals company restructured much of its research and development operations. Newton’s renowned as a pioneer of popular cholesterol drug Lipitor, which Forbes in 2008 called “the best-selling drug ever.”
